Outcome MeasureWell-being

WCS

Watts Connectedness Scale

2 Papers in Blossom

Outcome Data Across Studies

Reported results for WCS across 2 studies with quantitative data.

Outcome data across 9 study arm–timepoint observations
SD
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
2025Secondary
MBSR(active_comparator)01246.94.3—
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
2025Secondary
MBSR(active_comparator)141256.714.20.005
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
2025Secondary
MBSR(active_comparator)1801260.822.00.090
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
2025Secondary
MBSR + Psilocybin(experimental)01348.010.8—
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
2025Secondary
MBSR + Psilocybin(experimental)141376.413.80.005
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
2025Secondary
MBSR + Psilocybin(experimental)1801373.23.70.090
A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience
2026Secondary
Psilocybin group therapy(experimental)-141353.810.0—
A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience
2026Secondary
Psilocybin group therapy(experimental)81372.811.8—
A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience
2026Secondary
Psilocybin group therapy(experimental)1681267.517.3—

Papers Using WCS

Open Accessindividual

A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience

This Phase 1 study (n=13) tested a second group retreat psilocybin therapy session in people with metastatic cancer who had only partly responded before. It found no serious side effects, and anxiety and depression scores improved, with more participants reporting a full mystical experience after the second session.

Published
Authors
Back, A. L., McGregor, B. A., Thorn, L. L., Harvey, K., Blom, D., Callan, G., Guy, J., Kumar, S., Hershberg, R., Layer, M., Levin, J., Myers, S., Perez, J., Salmonson, K., Thompson, P., Whinney, J.
Open Accessindividual

Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial

This randomised controlled trial in 25 frontline physicians and nurses found that adding group psilocybin‑assisted psychotherapy (25 mg) to an 8‑week MBSR curriculum produced larger reductions in depressive symptoms at two weeks and greater improvements on burnout subscales, demoralisation and connectedness than MBSR alone. The intervention was well tolerated (only grade 1–2 adverse events, no serious AEs), suggesting that combining psilocybin with mindfulness training may be a promising treatment for COVID‑19‑related depression and burnout in healthcare providers.

Published
Journal
PLOS Medicine
Authors
Lewis, B. R., Hendrick, J., Byrne, K., Msph, M. O., Wu, C., Garland, E. L.

Quick Facts

Full Name
Watts Connectedness Scale
Domain
Well-being
Papers Indexed
2
Interpretation
Higher = better
All Measures